1. Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis 
Michael W. Konstan, Felix Ratjen 
Journal of Cystic Fibrosis 
Volume 11, Issue 2, Pages (March 2012)
DOI: /j.jcf
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1
Effect of dornase alfa on markers of inflammation over the 3-year BEAT study [26]. [reprint permission needed] Median neutrophils (% of total cell population), interleukin-8 levels, and elastase activity in bronchoalveolar lavage fluid (BALF) of patients randomized to treatment with dornase alfa or no dornase alfa treatment, at baseline and after 3years.
Journal of Cystic Fibrosis  , 78-83DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
Changes in MMP-9 concentrations in BAL fluid for patients who were untreated (A) or treated with dornase alfa (B) over 18months [24].
Journal of Cystic Fibrosis  , 78-83DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

4. Fig. 3
Benefit of increasing forced expiratory volume in 1second (FEV1) vs. slowing the rate of decline of FEV1[17].
Journal of Cystic Fibrosis  , 78-83DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

5. Fig. 4
Mean change in FEV1 from baseline through 96weeks in a study of children with early-stage CF lung disease [9].
Journal of Cystic Fibrosis  , 78-83DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

6. Fig. 5
Annual rates of decline in FEV1% predicted before and after index PFT in children and adults for the dornase alfa and comparator groups [18].
Journal of Cystic Fibrosis  , 78-83DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions